3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Withdrawn
3
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
184
Carboplatin
130
Paclitaxel
123
Gemcitabine
122
Docetaxel
96
Cyclophosphamide
89
Nivolumab
88
Cisplatin
87
Rituximab
71
Dexamethasone
68
Pemetrexed
64
Bevacizumab
64
Capecitabine
60
atezolizumab
54
fludarabine
49
Azacitidine
49
Fluorouracil
48
130-nm albumin-bound paclitaxel
43
venetoclax
41
Trastuzumab
41
Irinotecan
41
Cetuximab
40
Leucovorin
36
Ipilimumab
36
Erlotinib Hydrochloride
34
Fulvestrant
32
Cytarabine
32
avelumab
31
Oxaliplatin
31
Albumin-Bound Paclitaxel
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
INDUSTRY
×
angiotensin I (1-7)
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled